Follow Us On
Tablet
Files
Risperidone
Strength: 1mg
Count: 500
NDC
42291-976-50
Class
Rx
Brand Name
Risperdal
Imprint Code
R3;R
Color(s)
White
Shape
Oval
Score
No Score
Case Count
NA
Inactive Ingredients
Anhydrous Lactose, Sodium Lauryl Sulfate, Microcrystalline Cellulose (101), Colloidal Silicon Dioxide, Sodium Starch Glycolate (Type A), Magnesium Stearate, HPMC 2910/ Hypromellose, Macrogol/ PEG (MW 400), Macrogol/ PEG (MW 8000), Titanium Dioxide. Also, the tablet contains Polyvinyl Alcohol Part Hydrolyzed (used for 0.25, 0.5, 2, 3, 4 mg tablets), Macrogol/ PEG (MW 3350) (used for 0.25, 0.5, 2, 3, 4 mg tablets), Talc (used for 0.25, 0.5, 2, 3, 4 mg tablets), D&C Yellow #10 Aluminium Lake (used for 0.25, 4 mg tablets), FD&C Yellow #6/ Sunset Yellow FCF Aluminium Lake (used for 0.25, 2, 4 mg tablets), Iron Oxide Red (used for 0.5 mg tablets), Lactose Monohydrate, Triacetin & Stearic Acid (used for 1 mg tablets), FD&C Red #40/Allura Red AC Aluminum Lake (used for 2 mg tablets), Iron Oxide Yellow (used for 3 mg tablets) and FD&C Blue #1/ Brilliant Blue FCF Aluminium Lake (used for 4 mg tablets).
Indications and Usage
1.1 Schizophrenia Risperidone tablets are indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1)]. 1.2 Bipolar Mania Monotherapy Risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years). Adjunctive Therapy Risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults. 1.3 Irritability Associated with Autistic Disorder Risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years).
